Evidence map›Paper›PMID 41168491›Full record

ArticleMikrochimica acta2025

Sensitive chemiluminescent determination of CYFRA 21-1 as a lung cancer marker using PVP/NiO-supported luminol@ZIF-67-aptamer composite.

Jianjun Tang, ZhiQian Zhao, Yuxuan Xing, Sicong Jiang, Longhua Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jianjun TangRespiratory Department, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330200, P R China.
ZhiQian ZhaoDepartment of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan Province, China.
Yuxuan XingDepartment of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou University, Suzhou, 215026, Jiangsu Province, China.
Sicong JiangRespiratory Department, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330200, P R China. 18270200970@163.com.
Longhua SunRespiratory Department, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330200, P R China. sunlh089@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A chemiluminescent aptamer sensor (CL aptasensor) is  proposed for ultrasensitive determination of CYFRA21-1 as a lung cancer biomarker. The sensing mechanism of the CL aptasensor is  based on the incorporation of luminol into a cobalt-based metal-organic framework (MOF), also called ZIF-67, to generate a composite of the luminol@ZIF-67. This composite was then functionalized with a CYFRA21-1 specific aptamer (luminol@ZIF-67-apt) as signal probe. ssDNA was immobilized on PVP/NiO nanocomposite, allowing hybridization with the aptamer by complementary base pairing. In the presence of CYFRA 21-1, the luminol@ZIF-67-apt/PVP/NiO-ssDNA ternary complex could be assembled and induced intense chemiluminescence emission. Under the optimized conditions, the sensor showed a broad linear detection range  from 10⁻

Indexed as

Antigens, NeoplasmAptamers, NucleotideBiomarkers, TumorKeratin-19Luminescent MeasurementsLuminolLung NeoplasmsMetal-Organic FrameworksBiosensing TechniquesHumansImidazolesLimit of DetectionZeolitesantigen CYFRA21.1Antigens, NeoplasmAptamers, NucleotideBiomarkers, TumorImidazolesKeratin-19LuminolMetal-Organic FrameworksZeoliteszeolitic imidazolate framework-67Cell lung cancerChemiluminescenceCobalt-based metal–organic frameworkCytokeratin 19 fragmentPolyvinyl pyrrolidone/nickel oxide

Identifiers

PMID41168491

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.